Provided by Tiger Fintech (Singapore) Pte. Ltd.

SITE Centers Corp.

12.74
+0.08000.63%
Post-market: 12.740.00000.00%16:23 EDT
Volume:819.30K
Turnover:10.50M
Market Cap:667.96M
PE:0.93
High:12.98
Open:12.66
Low:12.66
Close:12.66
Loading ...

SITE Centers Announces Tax Estimate for Curbline Properties Distribution

Business Wire
·
26 Nov 2024

Undiscovered Gems With Strong Fundamentals In November 2024

Simply Wall St.
·
22 Nov 2024

Press Release: Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Dow Jones
·
18 Nov 2024

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

GlobeNewswire
·
18 Nov 2024

Press Release: Akoya Biosciences Reports Third Quarter 2024 Financial Results

Dow Jones
·
15 Nov 2024

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline

PR Newswire
·
14 Nov 2024

Press Release: Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Dow Jones
·
14 Nov 2024

MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update

GlobeNewswire
·
14 Nov 2024

Press Release: Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

Dow Jones
·
13 Nov 2024

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

GlobeNewswire
·
13 Nov 2024

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire
·
13 Nov 2024

Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

GlobeNewswire
·
13 Nov 2024

Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results

GlobeNewswire
·
13 Nov 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

ACCESSWIRE
·
12 Nov 2024

Press Release: IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Dow Jones
·
12 Nov 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

PR Newswire
·
11 Nov 2024